Clinical trials
Metabolic Dysfunction-Associated Liver Disease clinical trials
Below are recruiting metabolic dysfunction-associated liver disease clinical trials, each written for real people, not researchers. We’re tracking 105 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07660848RecruitingPhase 2
A study of two new injections for fatty liver disease with MASH
This trial tests two new injections (HRS-4729 and HRS-9531) for people with MASH, a type of fatty liver disease. The study aims to see if these drugs can help reduce liver fat and improve liver health.
Beijing, Beijing MunicipalityAges 18–75 - NCT06632457RecruitingPhase 3
Survodutide for NASH/MASH cirrhosis: a phase 3 trial
This study tests an investigational drug called survodutide for people with a type of fatty liver disease (NASH or MASH) that has progressed to cirrhosis. The goal is to see if it can improve liver health.
Peoria, ArizonaAges 18 years+ - NCT07165028RecruitingPhase 3
Study of new drugs for fatty liver with scarring
This trial tests new medicines for adults with fatty liver disease (MASLD) that has already caused some liver scarring. It aims to see if these drugs can help prevent the liver disease from getting worse.
Tuscaloosa, AlabamaAges 18 years+ - NCT07325526RecruitingPhase 2
Testing an experimental drug for liver cirrhosis caused by MASH
This study tests an investigational medicine (BI 3802876) in people with early-stage liver cirrhosis due to MASH. The goal is to see if it is well tolerated and potentially helpful.
Chandler, ArizonaAges 18–75 - NCT06528314RecruitingPhase 3
Efruxifermin for NASH-related cirrhosis
This study tests a new medication called efruxifermin for people with cirrhosis (liver scarring) caused by NASH, a type of fatty liver disease. The goal is to see if the drug can help improve liver health and prevent further damage.
Birmingham, AlabamaAges 18–80 - NCT07070362Recruiting
Digital early warning system for lung injury after liver surgery
This trial tests a digital early warning system to detect acute lung injury after liver surgery. It may help doctors catch breathing problems early so they can treat them faster.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06873165Recruiting
Gut bacteria treatment for fatty liver disease
This study tests whether a specially designed gut bacteria treatment can help people with fatty liver disease and related health issues like high blood sugar, high cholesterol, or high blood pressure. It aims to see if the treatment is safe and improves liver health.
TaipeiAges 18–70 - NCT07683065Recruiting
Secukinumab treatment in psoriasis patients with liver condition
This study looks at how well secukinumab works for psoriasis patients who also have a type of fatty liver disease called MASLD. It may help doctors understand if this treatment is a good option for people with both conditions.
Badalona, BarcelonaAges 18–100 - NCT07750535Recruiting
Liver fat and scarring in wheat-sensitive patients
This study looks at whether people with non-celiac wheat sensitivity or other digestive conditions have more fat in their liver or liver scarring. It aims to understand if wheat-related issues are linked to liver health.
Palermo, PalermoAges 18–65 - NCT07527910RecruitingPhase 2
Study of ALN-PNP with or without tirzepatide for fatty liver disease
This trial tests a new drug, ALN-PNP, alone or with tirzepatide in people with a specific genetic type of fatty liver disease. It aims to see if the combination reduces liver fat.
Coronado, CaliforniaAges 18–75 - NCT07288138RecruitingPhase 2
Study of a New Drug for MASH (Fatty Liver Disease)
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
Chandler, ArizonaAges 18–75 - NCT06867419Recruiting
Metabolic effects on fatty liver disease score
This study looks at how certain features of your metabolism affect a simple score (called the FAST score) in people with fatty liver disease (MASLD). It aims to help doctors better understand and manage the condition.
Tanta, GharbyeaAges 18 years+ - NCT06506513Recruiting
Can exercise help fatty liver disease?
This study tests whether a program of physical activity can reduce fat in the muscles and liver of people with MASLD, a type of fatty liver disease linked to metabolism. It looks at how exercise might help improve liver health.
BrusselsAges 18–70 - NCT07440511Recruiting
Spleen stiffness test for advanced liver scarring
This study tests a new way to measure liver scarring using a non-invasive ultrasound of the spleen (spleen stiffness measurement). It's for people with fatty liver disease (MASLD) who have advanced fibrosis (scarring) to see if this method can accurately detect the severity of liver damage.
RomeAges 18 years+ - NCT07534241Recruiting
Reishi Mushroom for Fatty Liver Disease
This study tests whether reishi mushroom (a type of fungus) can improve liver health in people with metabolic dysfunction-associated fatty liver disease—a condition where fat builds up in the liver. Researchers want to see if this natural supplement can reduce liver inflammation and improve blood sugar and cholesterol levels.
LahoreAges 35–65 - NCT07335601RecruitingPhase 2
Resmetirom for liver health after transplant in MASH patients
This trial tests an experimental drug, resmetirom, to see if it can help people who have had a liver transplant for MASH and now have fatty buildup in their new liver. It may also help people who had a transplant for other reasons but developed fatty liver afterward. The study focuses on those with moderate to advanced liver scarring (F2-F3).
La Jolla, CaliforniaAges 18–75 - NCT07090083Recruiting
Liver health and food support for children
This study tests whether providing fruit and vegetable vouchers to families with children who have fatty liver disease can improve liver health. Diet and lifestyle are key to managing this condition.
San Francisco, CaliforniaAges 6–17 - NCT07491458RecruitingPhase 2
Study of HU6 versus placebo for adults with MASH
This trial tests if HU6 is safe and effective for people with MASH, a type of fatty liver disease. You will either receive HU6 or a placebo to see how it affects your liver health.
Chandler, ArizonaAges 30 years+ - NCT07091539Recruiting
Fruit and vegetable vouchers for kids with fatty liver disease
This trial tests whether providing fruit and vegetable vouchers can help children with fatty liver disease (MASLD) improve their liver health. Families living in California with a child who has elevated BMI and liver enzymes may be eligible.
San Francisco, CaliforniaAges 6–17 - NCT06739330Recruiting
Thyroid function and fatty liver disease study
This study looks at how your thyroid might be linked to fatty liver disease (MAFLD). It aims to help researchers understand if thyroid problems play a role in this condition, which could lead to better treatments.
Tanta, El-GharbiaAges 18 years+ - NCT07381257RecruitingEarly Phase 1
Rifaximin for fatty liver disease
This trial tests if rifaximin, a gut medication, can help reduce liver fat in people with metabolic fatty liver disease. It may be an option if you have at least one metabolic risk factor and a certain amount of liver fat.
ShanghaiAges 18–75 - NCT07145151RecruitingPhase 2
Studying UBT251 for MASH liver disease
This trial tests a new medication called UBT251 for people with MASH, a type of liver disease linked to weight and metabolism. It aims to see if the medicine can reduce liver damage and scarring.
Beijing, Beijing MunicipalityAges 18–75 - NCT07463287Recruiting
Fatty liver and colorectal polyp risk study
This study looks at whether certain gene activity in people with fatty liver disease can predict the risk of developing colorectal polyps. It may help doctors find high-risk patients earlier.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06575400RecruitingPhase 1
Testing tolerance of BI 3804379 in healthy people and MASH patients
This study tests how well different doses of a new drug (BI 3804379) are tolerated. It is for healthy people and for patients with MASH (a type of fatty liver disease) who have advanced liver scarring.
EdegemAges 18–65
Hear when a new Metabolic Dysfunction-Associated Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metabolic dysfunction-associated liver disease?
- Yes. Clin2 currently lists 105 recruiting metabolic dysfunction-associated liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metabolic dysfunction-associated liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metabolic dysfunction-associated liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Metabolic Dysfunction-associated Fatty Liver Disease
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Metabolic Associated Fatty Liver Disease
- Metabolic Associated Steatotic Liver Disease
- Liver Dysfunction
- Alcohol-associated Liver Disease
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.